Tradestie Institutional Equity Comparison Engine

AZN vs CING โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AZN Overall Edge

AZN Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AstraZeneca PLC (AZN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AZN trades at 16.3x Forward P/E with 25.8% operating margin (+6.7% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AZN sits in UNCLASSIFIED (8th %ile IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner AZN
AZN 16.3x vs CING N/M Fwd P/E
Growth & Margin Winner AZN
Op Margin 25.8% vs 0.0% ยท YoY +6.7% vs +0.0%
Momentum & Technical Winner AZN
1Y +2.2% vs +35.4% ยท 52W Pos 48% vs 18%
Options & Structure Winner AZN
UNCLASSIFIED (8th %ile IV) vs BREAKDOWN (16th %ile IV)
AZN NASDAQ
AstraZeneca PLC
Pharmaceutical Preparations
$182.16
-1.01% 1D
Market Cap $286.1B
1M Return +11.11%
1Y Return +2.22%
Forward P/E 16.3x
Unified AI Score
44.8 / 100 HOLD
Tech 32.0 Fund 38.0 Flow 50.0 Mom 40.0
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap $62.5M
1M Return +8.37%
1Y Return +35.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AZN +2.22% CING +35.39% Spread: +33.17 pp (CING Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AZN TTM Op. Margin: 25.8% CING TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AZN vs CING. Trailing 12-month operating profitability (AZN 25.8% vs CING 0.0%) and valuation multiples (AZN 16.3x vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AZN (9) vs CING (0)
Institutional Metric AZN CING Criterion Row Winner
Market Capitalization Scale $286.1B $62.5M Larger Scale AZN
Trailing P/E Ratio Valuation 26.1x N/M Lower Multiple AZN
Forward P/E Ratio Valuation 16.3x N/M Lower Multiple AZN
Revenue Growth (YoY) Growth +6.7% +0.0% Higher Growth AZN
Operating Margin (TTM) Profitability 25.8% 0.0% Higher Margin AZN
Net Profit Margin Profitability 17.7% 0.0% Higher Margin AZN
Return on Equity (ROE) Capital Efficiency 22.6% -198.7% Higher ROE AZN
52-Week Range Position Momentum 48% ($153โ€“$213) 18% ($3โ€“$12) Stronger Trend AZN
Beta / 30D Volatility Risk Regime 0.04ฮฒ ยท 32% Vol 1.07ฮฒ ยท 121% Vol Lower Realized Risk AZN
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AZN vs CING Buy Guide
AZN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live AZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AZN nor CING registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.